INVA
$14.08
Innoviva
($.55)
(3.76%)
INVA
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  $2.65
Revenue:  $103.42 Mil
Wednesday
Oct 26
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when INVA reports earnings?
Beat
Meet
Miss

Where is INVA's stock price going from here?
Up
Flat
Down
Stock chart of INVA
Analysts
Summary of analysts' recommendations for INVA
Score
Grade
Pivots
Resistance
$14.82
$14.64
$14.36

$14.18

Support
$13.90
$13.72
$13.44
Tweet
Growth
Description
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.